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1  | INTRODUC TION
In general, HIV-negative men who have sex with men (MSM) have 
been considered to be at low risk for hepatitis C virus (HCV) infec-
tion.1,2 HIV-negative MSM who access pre-exposure prophylaxis 
(PrEP) have reported sexual behaviours that could place them at 
high risk of HCV, including high partner numbers, chemsex and in-
jecting drug use.3,4 Early diagnosis of HCV infection allows early 
linkage to treatment and care, and reduction in onward trans-
mission of infection.5 Data from European PrEP trials and cohort 
studies of PrEP users have reported high baseline HCV prevalence 
and incidence during follow-up.6-8 In contrast, studies from North 
America have generally found low levels of HCV endemicity among 
PrEP users.9-11
The PROUD study was an open-label trial of HIV PrEP among 
544 HIV-negative MSM.12,13 As there were no data on HCV inci-
dence in HIV-negative MSM using PrEP in the UK, we implemented 
routine quarterly screening during the long-term follow-up phase 
when all participants had access to PrEP. We report HCV prevalence 
and incidence among participants in the PROUD study.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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2  | MATERIAL S AND METHODS
PROUD was an open-label, wait-list trial design that randomized 
MSM attending participating sexual health centres in England 
to receive HIV PrEP immediately or after a deferral period of 
1 year (the deferred phase). Five hundred and forty-four par-
ticipants were recruited between November 2012 and April 
2014, and follow-up continued to October 2016. The protocol 
was modified in November 2014 following an interim analysis 
which showed PrEP to be highly effective, resulting in some par-
ticipants in the deferred arm being offered PrEP earlier than one 
year (N = 163).13
The initial PROUD protocol followed national guidelines on HCV 
testing, with screening 'on indication'. Screening at enrolment was 
not mandated. The tests used during the trial varied by site, and the 
use of antibody, antigen or viral load tests depending on whether the 
participant had a prior history of HCV. Information on HCV was col-
lected in a number of ways. At enrolment, participants self-reported 
a diagnosis with HCV in the previous 12 months, and the clinician 
reported whether the participant had ever been screened for, and if 
so, diagnosed with HCV. At each visit, the number of HCV screens 
and positive screens (although not distinguishing the type of test) 
since the previous visit was recorded. For all new infections, clinics 
were asked to provide detailed clinical and laboratory information, 
including dates of last positive and last negative test (for all assays), 
HCV viral load test results, liver function test results and history of 
injecting drug use. In March 2015, additional funding was acquired 
which allowed screening at every quarterly study visit; at this time, 
all participants had access to PrEP and the trial was closed to further 
recruitment.
If the first HCV antibody (anti-HCV) test was negative, the par-
ticipant was assumed to be seronegative at enrolment. If the first 
test was positive, the Trial Management Group determined whether 
infection was most likely acquired before enrolment (and thus con-
tributed to the seroprevalence analysis) or after enrolment (and 
thus contributed to the incidence analysis) based on alanine trans-
aminase and HCV viral load measurements, in relation to time since 
randomization.
2.1 | Statistical analysis
The cumulative incidence of HCV infection (time to diagnosis) was 
estimated using Kaplan-Meier analysis and randomized groups com-
pared with the log-rank test, censoring at the time of the last screen 
for HCV. Estimation of incidence by calendar year was complicated 
by the highly variable time between the last negative test and the 
first positive test which, in some cases, could span adjacent calendar 
years. To address this, the date of infection was imputed 1000 times 
assuming a uniform distribution, and calculating the incidence for 
each calendar year within each imputed dataset.14 Estimates were 
obtained by averaging across the imputed datasets, and confidence 
intervals derived using Rubin's rule.15 All analyses were done in 
STATA version 15.1.
F I G U R E  1   Hepatitis C screening and infection consort diagram. Seroprevalent infections indicated by dashed box. Incidence infections 
indicated by double-lined box. TMG, Trial Management Group
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3  | RESULTS
Characteristics of the 544 study participants have been previously 
described.13 Figure 1 illustrates the hepatitis C screening and in-
fection among study participants. One hundred and thirty-three 
(24.4%) participants were screened for HCV at enrolment, and 
499 (91.7%) were tested at least once during follow-up. Nine par-
ticipants were only screened at baseline and therefore could not 
contribute to an incidence analysis. A HCV screen was conducted 
at 54.0% (3213/5946) of visits (higher during the phase of routine 
quarterly screening [80.6%] compared to the earlier phase of test-
ing on indication [34.9%]), with a median of 6 (IQR: 3-8) screens per 
participant. Of the 45 participants who were never tested, 14 par-
ticipants were also missing information on HCV history collected 
at enrolment.
3.1 | Hepatitis C seroprevalence at enrolment
The seroprevalence at enrolment was 2.1% (11/530; 95% CI: 1.0%-
3.7%). The 11 cases were identified as follows: eight participants 
were reported by the clinician at enrolment to have had a previ-
ous diagnosis of HCV; two were diagnosed with HCV a few days 
before enrolment; two participants had HCV viraemia detected 
at their first post-enrolment test (they were not tested at enrol-
ment), of which one was judged to have acquired infection before 
enrolment.
3.2 | Hepatitis C incidence
HCV incidence is based on the 490 participants who were con-
sidered HCV seronegative at enrolment, or who had previously 
cleared HCV infection prior to enrolment, and had at least one post-
enrolment HCV test. Table 1 presents baseline characteristics of 
these participants and indicates a cohort with high-risk behaviours: 
226 (47.6%) reported use of chemsex-associated drugs in the past 
three months, 282 (57.6%) were diagnosed with any STI in the past 
12 months, 170 (36.9%) reported using post-exposure prophylaxis in 
the past 12 months, and the median number of partners in the past 
three months was 10.
The median follow-up (enrolment to last HCV test) was 2.6 
(IQR: 2.1-3.0) years, with a total follow-up of 1188.8 person-years 
(PY). Overall, 25 participants had a new HCV infection, yielding 
an incidence rate of 2.1 per 100 PY (25/1188.8; 95% CI: 1.4-3.1). 
Three of these were re-infections (the previous infections had 
cleared spontaneously or with treatment before enrolment), and 
one participant experienced two infections during follow-up (only 
the first infection was included in the incidence calculation). Two 
HCV infections were acquired after diagnosis of HIV whilst the par-
ticipant was no longer on PrEP but was being actively followed up. 
Excluding these cases from the HCV incidence calculation reduced 
the estimate only slightly (1.9 per 100 PY [95% CI: 1.2-2.9]). Use of 
nonprescribed injected drugs was reported by 11 participants at 
the suspected time of HCV infection, was denied by 12 and was 
unknown for two.
Figure 2 shows the cumulative incidence of time to a new HCV di-
agnosis, stratified by randomized arm (P-value log-rank test = 0.87). 
As only three infections (one immediate, two deferred) were ob-
served during the deferred phase of the study (ie the period before 
the DEF arm had access to PrEP), the trial essentially provides no 
randomized information of whether access to PrEP affects the risk 
of acquiring HCV infection. Accounting for uncertainty in the time 
of acquisition of HCV infection, HCV incidence appeared to increase 
over calendar time (Table 2), reaching an estimated 4.0 per 100 PY in 
2016 (95% CI: 2.0-8.1, P-value for trend = 0.09).
TA B L E  1   Baseline characteristics of PROUD participants 










University degree 303 (62.3%)
Full-time employment 351 (72.4%)
Born in the UK 292 (60.1%)
Relationship status
Partner, living together 145 (29.8%)
Partner, living separately 74 (15.2%)
Single 267 (54.9%)
Circumcised 142 (29.4%)
Chemsex-associated drugs* 226 (47.6%)
STI diagnosed in past 12 mo
Any** 282 (57.6%)
Rectal*** 162 (34.8%)
Rectal*** or syphilis 183 (39.3%)
Number of sexual partners in past 3 mo, median 10 (5-20)
Number of ncRAI partners in past 3 mo, median 2 (1-5)
Number of HIV tests in past 12 mo 3 (2-4)
Use of PEP in past 12 mo 170 (36.9%)
Note: Data are median (IQR) or n (%). Number of participants missing 
baseline data: ethnicity, 5; university degree, 4; full-time employment, 
5; relationship status, 4; chemsex, 15; STI, 24; total number of partners, 
8; ncRAI partners, 25; HIV test, 17; PEP, 29.
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency 
virus; ncRAI, receptive anal intercourse without a condom; PEP, post-
exposure prophylaxis; STI, sexually transmitted infection; UK, United 
Kingdom.
*Methamphetamine, GHB, mephedrone or ketamine. 
**Chlamydia, gonorrhoea, or syphilis. 
***Rectal chlamydia or rectal gonorrhoea. 
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4  | DISCUSSION
This analysis demonstrates a high overall incidence of hepatitis C 
infection (2.1 per 100 PY) in the PROUD trial. This is higher than, 
although compatible with, the incidence reported in other contem-
poraneous PrEP studies in Europe. In the AmPrEP study, HCV inci-
dence during follow-up was 1.9 per 100 PY (95% CI: 1.1-3.4). The 
incidence rate of primary infection was 1.0 per 100 PY (95% CI: 
0.5-2.2) and of re-infection 25.5 per 100 PY (95% CI: 11.5-56.8).6 In 
the ANRS IPERGAY study of on-demand PrEP, HCV incidence was 
estimated to be 1.4 per 100 PY (95% CI: 0.7-2.4).7 A large French co-
hort estimated HCV incidence to be 1.2 per 100 PY for HIV-negative 
MSM PrEP users.8
In contrast, demonstration and implementation cohorts of PrEP 
users in North America have reported lower incidence of HCV in-
fection. An incidence of 0.7 per 100 PY (95% CI: 0.08-2.4) was re-
ported from a San Francisco clinic.10 A retrospective cohort study in 
a Montreal sexual health clinic that compared the incidence of STIs 
prior to, and in 12 months following, the prescription of PrEP in 109 
MSM found no incident cases of HCV during either time period.9 
The disparity in HCV incidence seen between European and North 
American PrEP studies could be due to a different risk of exposure 
to the virus (ie variation in the prevalence of active infection among 
MSM) or differences in the extent of high-risk sexual behaviours. 
PROUD participants were at the far end of this spectrum, reporting 
an average of 10 sexual partners in the three months before enrol-
ment and 37% having used post-exposure prophylaxis in the previ-
ous 12 months (Table 1).
Few studies have estimated HCV incidence in general HIV-
negative MSM populations. A meta-analysis by Ghisla et al estimated 
incidence to be 0.43 per 1000 PY (95% CI: 0.01-0.86).2 A cohort in 
Amsterdam did not observe any HCV infections in HIV-negative par-
ticipants during 7808 PY of follow-up (0 per 1000 PY, 95% CI: 0.0-
0.5).16 In a UK (Brighton) hospital, HCV incidence was estimated at 
0.15 per 100 PY (95% CI: 0.05-0.35)17 among 57% of eligible partic-
ipants who were tested. The difference in HCV incidence between 
HIV-negative MSM in general and those seeking PrEP is likely to be 
explained by the lower sexual risk behaviours and lower testing rates 
in the former group.
Although the increase in HCV incidence over calendar timein 
PROUD was not conventionally statistically significant, the low sero-
prevalence at enrolment (2.1%, coincidently identical to the overall 
incidence of 2.1% per year) suggests that the increasing incidence 
is genuine. This increase occurred despite an overall decline in HCV 
prevalence in England in recent years.18 Phylogenetic analysis of 
HCV infections in the AmPrEP study and a cohort of HIV-negative 
F I G U R E  2   Cumulative incidence of 
HCV infection (time from enrolment to 
diagnosis). For illustrative purposes, one 
participant (IMM) diagnosed 4 d before 
the end of the trial is excluded. (P-value 
for log-rank test = 0.87)
Year Person-years follow-up
Estimated no. of HCV 
infectionsa 
Rate per 100 PY 
(95% CI)*
2013 154.8 2.8 1.8 (0.5-6.2)
2014 431.4 5.7 1.3 (0.5-3.3)
2015 393.2 8.2 2.1 (1.0-4.4)
2016 205.1 8.2 4.0 (2.0-8.1)
aAccounting for infection interval over calendar years. 
*P-value for trend = 0.09. 
TA B L E  2   HCV incidence stratified by 
calendar year
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and HIV-positive MSM in a French clinic19,20 suggest that there was 
substantial sexual mixing between HIV-negative and HIV-positive 
populations, who have high HCV prevalence21 and incidence,2,22 and 
it is likely that PrEP facilitates this mixing. Although the frequency 
of HCV testing increased part way through the study and probably 
resulted in more rapid diagnosis of infections, we used an imputation 
method that should correct for any bias arising from this.
The 2.1% seroprevalence of HCV in PROUD participants at en-
rolment was considerably lower than that reported in the AmPrEP 
demonstration project (4.8%).19 The IPERGAY study reported only 
one HCV infection at enrolment.7 However, HCV seroprevalence 
changes rapidly in the context of a high incidence and comparisons 
between studies will be affected by the calendar time over which 
seroprevalence was calculated.
Our study has two major limitations. First, the small number of 
incident HCV infections limited our ability to examine risk factors 
for the acquisition of HCV, including geographical region. The sec-
ond limitation is around the generalizability of our findings. PROUD 
participants were at much higher risk of acquiring HIV infection than 
other MSM attending sexual health clinics in the same time period, 
and the same may apply to HCV infection. The use of nonprescribed 
injected drugs was reported by 11 of the 25 incident cases, and this 
cannot be excluded as a possible route of transmission. However, 
qualitative research indicates that sharing of needles is uncommon 
among MSM injecting chemsex drugs in the UK, with high awareness 
of the risks of doing so.23 Even if these 11 cases are discounted, the 
estimated incidence is still high, suggesting that HCV is highly trans-
missible through sexual contact, with the risk of epidemic spread of 
the infection in certain populations.
Regular care for PrEP provides an opportunity to screen for 
and provide early intervention for HCV. The increasing availability 
of HCV antigen/antibody testing makes screening in this popula-
tion more feasible.24 The high incidence of HCV that we observed 
in PROUD supports the 2018 BHIVA/BASHH recommendation 
for quarterly HCV testing among HIV-negative MSM using PrEP in 
the UK, in line with other STIs.25 Also, a recent modelling study has 
indicated that screening and treating PrEP users for HCV at least 
every 12 months can reduce HCV incidence by 67.3% (uncertainty 
range 52.7%-79.2%).26 However, HCV incidence can vary markedly 
by location and time, and guidance in the UK and other countries27,28 
should be regularly reviewed in the light of local evidence.
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